Renal denervation after symplicity HTN-3: An update

Current Hypertension Reports

Volumn 16, Issue 8, 2014, Pages

  Persu, Alexandre ^a,b   Jin, Yu ^c   Fadl Elmula, Fadl Elmula Mohamed ^d   Jacobs, Lotte ^c   Renkin, Jean ^a,b   Kjeldsen, Sverre ^d  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Ambulatory blood pressure; Blinding; Renal artery stenosis; Renal denervation; Resistant hypertension; White coat effect

Indexed keywords

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; ELECTROSTIMULATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY FUNCTION; MORBIDITY; MORTALITY; PRESSORECEPTOR; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); COMPLICATION; DENERVATION; HYPERTENSION; KIDNEY DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DENERVATION; ELECTRIC STIMULATION; HUMANS; HYPERTENSION; KIDNEY DISEASES;

EID: 84901860522     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0460-x     Document Type: Article

References (88)

1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
2. •• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9. Despite its limitations and methodological biases, this small open randomised trial generated a huge wave of enthusiasm, with up to 15 to 20,000 renal denervations performed in Europe, until Symplicity HTN-3 disclosed that many of the apparent benefits of renal denervation may be explained by patient and physician-related biases.
3. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.
4. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:231-41.
5. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol. 2012;60:2422-4.
6. VerloopWL,Vink EE,Voskuil M, et al. Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens. 2013;31:1662-8.
7. • Persu A, Jin Y, Baelen M, et al. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension. 2014;63: 1319-25. Analysis of 731 patients referred for renal denervation to 11 European expert centres. Careful screening and treatment adjustment removed indication of renal denervation in two-thirds of patients. The most frequent reason for ineligibility was blood pressure control after drug treatment adjustment in the expert centre.
8. Persu A, Jin Y, Azizi M, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150-6.
9. Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526-32.
10. Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension. 2013;62:450-2.
11. Ezzahti M, Moelker A, Friesema EC, van der Linde NA, Krestin GP, van den Meiracker AH. Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension. J Hypertens. 2014;32:135-41.
12. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-40.
13. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596-606.
14. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012;30:874-6.
15. Azizi M, Steichen O, Frank M, Bobrie G, Plouin PF, Sapoval M. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg. 2012;43:293-9.
16. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423-31.
17. Vaclavik J, Sedlak R, PlachyM, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-75.
18. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824 - 30.
19. •• Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart. 2013;99:1579-87. Based on a meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design, the authors predicted that office blood pressure decrease after renal denervation would converge with that of ambulatory blood pressure - and thus substantially shrink - in a blinded randomised study. This dense paper contains many interesting thoughts about possible biases in an open randomised study such as Symplicity HTN-2.
20. Demaria AN. Reflections on renal denervation. J Am Coll Cardiol. 2014;63:1452-3.
21. •• Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63: 991-9. This carefully designed randomised study shows that, in patients with truly resistant hypertension and drug adherence demonstrated by drug witnessed intake, treatment adjustment is much superior to renal denervation.
22. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.
23. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901-9.
24. Brandt MC, Reda S, Mahfoud F, Lenski M, Bohm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60:1956-65.
25. Ukena C, Mahfoud F, Spies A, et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2013;167:2846-51.
26. Himmel F,Weil J, ReppelM, et al. Improved heart rate dynamics in patients undergoing percutaneous renal denervation. J Clin Hypertens (Greenwich). 2012;14:654-5.
27. Tsioufis C, Papademetriou V, Tsiachris D et al. Drug-resistant hypertensive patients responding to multielectrode renal denervation exhibit improved heart rate dynamics and reduced arrhythmia burden. J Hum Hypertens 2014. doi:10.1038/jhh.2014.14
28. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60: 419-24.
29. Ott C, Mahfoud F, Schmid A, Ditting T, et al. Improvement of albuminuria after renal denervation. Int J Cardiol. 2014;173:311-5.
30. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6.
31. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-7.
32. Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163-70.
33. Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162:189-92.
34. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
35. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991-6.
36. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-41.
37. Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031-45.
38. Ziegler AK, Bertog S, Kaltenbach B et al. Efficacy and safety of renal denervation in elderly patients with resistant hypertension. Catheter Cardiovasc Interv 2013. doi:10.1002/ccd.25166
39. Giordano A, Polimeno M, Messina S, et al. Transcatheter renal sympathetic denervation despite angiographically significant proximal stenosis: proof of concept from a case report. Int J Cardiol. 2014;172:224-5.
40. Bausback Y, Friedenberger J, Hertting K, et al. Renal denervation for hypertension refractory to renal artery stenting. J Endovasc Ther. 2014;21:181-90.
41. Pessina AC, Bisogni V, Fassina A, Rossi GP. Munchausen syndrome: a novel cause of drug-resistant hypertension. J Hypertens. 2013;31:1473-6.
42. •• Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-401. In this large, US randomised trial including a sham procedure, the benefit assignable to renal denervation was found to be < 3 mmHg vs. 25-30 mmHg in Symplicity HTN-2 and other previous studies. The most likely explanation accounting for this huge discrepancy is blinding, which minimised patient and physician-related biases in Symplicity HTN-3. The failure of Symplicity HTN-3 to meet its primary endpoint shows unequivocally that renal denervation is not ready for clinical dissemination.
43. Sapoval M, Azizi M. Renal artery denervation for the treatment of resistant hypertension. Update after Medtronic announcement that its Symplicity HTN3 study failed to meet its primary efficacy end point. Diagn Interv Imaging. 2014;95:353-4.
44. Myers MG, Wijeysundera HC. Renal Nerve Denervation-A Hypertension Bubble? J Clin Hypertens (Greenwich) 2014. doi: 10.1111/jch.12334
45. Floras JS. Renal denervation for drug-resistant hypertension: suffering its original sin, seeking redemption. Can J Cardiol. 2014;30: 476-8.
46. Baker NC,Waksman R. Editorial: renal sympathetic denervation: a true lack of efficacy, or the victim of a "perfect storm"? Cardiovasc Revasc Med. 2014;15:61-2.
47. Jin Y, Jacobs L, Baelen M, et al. Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press. 2014;23:138-46.
48. Schirmer SH, Sayed MM, Reil JC, et al. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol. 2014;63:1916-23.
49. Persu A, Renkin J, Asayama K, O'Brien E, Staessen JA. Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence. Expert Rev Cardiovasc Ther. 2013;11:739-49.
50. Mahfoud F, Urban D, Teller D et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J 2014. doi:10.1093/eurheartj/ehu093
51. Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60:1271-7.
52. Dorenkamp M, Bonaventura K, Leber AW, et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J. 2013;34:451-61.
53. Lambert GW, Hering D, Esler MD, et al. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension. 2012;60:1479-84.
54. O'Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731-68.
55. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622-9.
56. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.
57. Kaltenbach B, Id D, Franke JC, et al. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60:2694-5.
58. Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012;8:57-61.
59. Bacaksiz A, Uyarel H, Jafarov P, Kucukbuzcu S. Iatrogenic renal artery stenosis after renal sympathetic denervation. Int J Cardiol. 2014;172:e389-90.
60. Jaén Águila F, Mediavilla Garcia JD, Navarro EM, Vargas Hitos JA, Fernandez-Torres C. Bilateral renal artery stenosis after renal denervation. Hypertension. 2014;63:e126-7.
61. Chandra AP, Marron CD, Puckridge P, Spark JI. Severe bilateral renal artery stenosis after transluminal radiofrequency ablation of renal sympathetic nerve plexus. J Vasc Surg 2014. doi:10.1016/j.jvs.2013.11.005
62. Kaiser L, Beister T,Wiese A, et al. Results of the ALSTER BP realworld registry on renal denervation employing the Symplicity system. EuroIntervention. 2014;10:157-65.
63. Raman B, Pathik B, Bridgman C. Recurrent pulmonary oedema after percutaneous radiofrequency renal denervation. Int J Cardiol. 2014;174:e42-3.
64. Versaci F, Trivisonno A, Olivieri C, Caranci F, Brunese L, Prati F. Late renal artery stenosis after renal denervation: is it the tip of the iceberg? Int J Cardiol. 2014;172:e507-8.
65. Versaci F, Trivisonno A, Olivieri C, Magri G, Caranci F, Prati F. Is an abnormal vascular response after renal sympathetic denervation predictive of permanent damage? An unusual case of late renal artery stenosis after energy delivery. J Endovasc Ther. 2014;21:191-6.
66. Worthley SG, Tsioufis CP,WorthleyMI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132-40.
67. Pucci G, Battista F, Lazzari L, Dominici M, Boschetti E, Schillaci G. Progression of renal artery stenosis after renal denervation. Impact on 24-hour blood pressure. Circ J. 2014;78:767-8.
68. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53.
69. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009;151:1-2.
70. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-81.
71. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet. 2003;361:1629-41. (Pubitemid 36579003)
72. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57: 898-902.
73. Hayek SS, Abdou MH, Demoss BD, et al. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens. 2013;26:1452-8.
74. •• Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-74. Drug dosages in the urine show that up to 50%of patients with apparently resistant hypertension do not take or take only a few of the drugs prescribed. Changes in drug adherence may have a major impact on the apparent benefits of renal denervation, especially in observational and open randomised trials.
75. Rosa J, Zelinka T, Petrak O et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens 2014. doi:10.1038/jhh.2014.3
76. Rimoldi SF, Scheidegger N, Scherrer U, et al.Anatomical eligibility of the renal vasculature for catheter-based renal denervation in hypertensive patients. JACC Cardiovasc Interv. 2014;7:187-92.
77. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-310. (Pubitemid 32804122)
78. Vrijens B,Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-7. (Pubitemid 351731741)
79. Esler M. Renal denervation for hypertension: observations and predictions of a founder. Eur Heart J. 2014;35:1178-85.
80. • ChinushiM, Izumi D, IijimaK, et al. Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery. Hypertension. 2013;61:450-6. In the animal, electrical stimulation of renal arteries elicits a sympathetic reaction that is abolished by renal denervation. This approach may prove helpful to evaluate completeness of renal denervation and predict blood pressure response to renal denervation in man.
81. • Persu A,O'Brien E,Verdecchia P. Use of ambulatory blood pressure measurement in the definition of resistant hypertension: a review of the evidence. Hypertens Res 2014. doi:10.1038/hr.2014.83. This review summarises the evidence in favour of the superiority of ambulatory over office blood pressure for the diagnosis of resistant hypertension. Ambulatory, not office, blood pressure should be used in trials testing new drugs or interventions in patients with resistant hypertension, both for patients selection and treatment evaluation
82. Pellerin O, Sapoval M, Trinquart L, et al. Accuracy of multi-detector computed tomographic angiography assisted by postprocessing software for diagnosis atheromatous renal artery stenosis. Diagn Interv Imaging. 2013;94:1123-31.
83. Persu A, Azizi M, Jin Y et al. Hyper-responders vs non-responder patients after renal denervation : do they differ? J Am Soc Hypertens 2014;8(4), Supplement: e117
84. Stamatakis E, Weiler R, Ioannidis JP. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Investig. 2013;43:469-75.
85. HanselinMR, Saseen JJ, Allen RR,Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58:1008-13.
86. Campese VM. Interventional hypertension: a new hope or a new hype? The need to redefine resistant hypertension. J Hypertens. 2013;31:2118-21.
87. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-73.
88. Brouwers S, Dolan E, Galvin J, et al. Creation of an iliofemoral arteriovenous fistula in patients with severe hypertension: a prospective open label multi-center pilot study. J Hypertens. 2013;31(e-supple A):e103.